These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35409110)

  • 1.
    Jin TY; Park KS; Nam SE; Yoo YB; Park WS; Yun IJ
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
    Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
    Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
    Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer.
    Shen Y; Xue J; Yu J; Jiang Y; Bu J; Zhu T; Gu X; Zhu X
    World J Surg Oncol; 2022 Dec; 20(1):398. PubMed ID: 36517818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
    Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of Prognostic and Immune Infiltrates for RAD51 in Human Breast Cancer.
    Li F; Zhang Y; Shi Y; Liu S
    Crit Rev Eukaryot Gene Expr; 2021; 31(4):71-79. PubMed ID: 34587437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
    Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
    Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
    Holstege H; van Beers E; Velds A; Liu X; Joosse SA; Klarenbeek S; Schut E; Kerkhoven R; Klijn CN; Wessels LF; Nederlof PM; Jonkers J
    BMC Cancer; 2010 Aug; 10():455. PubMed ID: 20735817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
    Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
    J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
    Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
    BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations and expressions of breast cancer 1/2 in lung cancer.
    Yan B; Xie B; Huang M; Guo J; Sun J; Chen J; Tao Y; Xiao D
    Thorac Cancer; 2023 Jun; 14(18):1753-1763. PubMed ID: 37160413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
    Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
    Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
    BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
    Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
    Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
    Hallajian Z; Mahjoubi F; Nafissi N
    Breast Cancer; 2017 Jul; 24(4):624-634. PubMed ID: 28058614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.